CONTEXT
Bacteria that are frequently involved in the clinic may be resistant or even multi-resistant to antibiotics (MRB).
The lack of new antibiotic solutions or new adjuvants sometimes leads patients to therapeutic dead-ends that can be fatal.
DESCRIPTION
The laboratory has shown that the combination of a calixarene with an antibiotic could give a new threshold of sensitivity to a bacterium resistant to this antibiotic.
This association tested with a large panel of antibiotics on three of the most dangerous MRB (Pseudomonas aeruginosa, E. Coli and Streptococcus aureus multi resistant) concludes that there is a synergy or additivity for some couples on these BMRs.
After having concluded in the non-toxicity of calixarene 1, in vivo investigations will be carried out on mice infected by Pseudomonas aeruginosa and on contaminated murine lungs.
COMPETITIVE ADVANTAGES
New adjuvant in antibacterial control
Synergistic or additive action
Non-toxic in murine
MARKETS AND APPLICATIONS
Pharmaceutical
DEVELOPMENT STAGE
TRL 3 in vitro studies
INTELLECTUAL PROPERTY
Patent issued in 2013
TARGET PARTNERSHIP
Patent licensing
CONTACT
Thomas BLUM
Business Developer
+33 (0)6 17 06 68 07
thomas.blum@sayens.fr